A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 17, 2026 → Dec 17, 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 17, 2026 to Dec 17, 2027
    • Interventions: CD371-specific/YSNVz/I-18 CAR T cells (Biological) to CD371-specific/YSNVz/I-18 CAR T cells (Biological)
    • Eligibility criteria expanded, about 128 words
    • Publications: details revised at 1 of 1 entry
  2. Primary and study completion pushed from Aug 22, 2026 to Dec 17, 2026
    • Start date: Aug 22, 2023 to Sep 1, 2023
    v11
  3. Re-verified, no change to tracked fieldsv10
  4. Eligibility criteria expanded, about 15 wordsv9
  5. 2 versions Re-verified since Jan 17, 2025, no change to tracked fieldsv7-v8
Show 5 earlier versionsHide 5 earlier versions
  1. Enrollment target: 18 to 15v6
  2. Enrollment target: 6 to 18
    • Interventions: CD371-YSNVZ-IL18 CAR T cells (Biological) to CD371-specific/YSNVz/I-18 CAR T cells (Biological)
    • Study arms: 2 to 3
    v5
  3. 2 versions Re-verified since Dec 19, 2023, no change to tracked fieldsv3-v4
  4. Interventions: CAR T cells (Biological) to CD371-YSNVZ-IL18 CAR T cells (Biological)v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.
Trial Details
NCT Number NCT06017258
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Related terms Leukemia, Myeloid, Acute
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov